Published in Nat Neurosci on June 07, 2009
RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron (2013) 4.67
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein. Neuron (2009) 3.15
The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease. Nat Rev Neurosci (2010) 3.14
LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet (2009) 2.55
Rapamycin activation of 4E-BP prevents parkinsonian dopaminergic neuron loss. Nat Neurosci (2009) 2.35
Loss of leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A (2010) 2.34
R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice. Proc Natl Acad Sci U S A (2009) 2.28
Enhanced striatal dopamine transmission and motor performance with LRRK2 overexpression in mice is eliminated by familial Parkinson's disease mutation G2019S. J Neurosci (2010) 2.20
Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One (2011) 1.93
Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol (2010) 1.88
Interplay of LRRK2 with chaperone-mediated autophagy. Nat Neurosci (2013) 1.88
The neuropathology of genetic Parkinson's disease. Mov Disord (2012) 1.73
Dopamine release in the basal ganglia. Neuroscience (2011) 1.67
GTPase activity plays a key role in the pathobiology of LRRK2. PLoS Genet (2010) 1.63
Impaired dopaminergic neurotransmission and microtubule-associated protein tau alterations in human LRRK2 transgenic mice. Neurobiol Dis (2010) 1.60
Molecular and clinical prodrome of Parkinson disease: implications for treatment. Nat Rev Neurol (2010) 1.57
Parkinson's disease: insights from pathways. Hum Mol Genet (2010) 1.52
Classic and new animal models of Parkinson's disease. J Biomed Biotechnol (2012) 1.45
Axon degeneration in Parkinson's disease. Exp Neurol (2012) 1.40
Phosphorylation-dependent 14-3-3 binding to LRRK2 is impaired by common mutations of familial Parkinson's disease. PLoS One (2011) 1.38
Adult neurogenesis and neurite outgrowth are impaired in LRRK2 G2019S mice. Neurobiol Dis (2010) 1.35
LRRK2 kinase regulates synaptic morphology through distinct substrates at the presynaptic and postsynaptic compartments of the Drosophila neuromuscular junction. J Neurosci (2010) 1.35
Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener (2012) 1.34
GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1. PLoS Genet (2012) 1.29
MKK6 binds and regulates expression of Parkinson's disease-related protein LRRK2. J Neurochem (2010) 1.28
LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity. Nat Neurosci (2014) 1.24
A comparative study of Lrrk2 function in primary neuronal cultures. Parkinsonism Relat Disord (2010) 1.23
Impaired inflammatory responses in murine Lrrk2-knockdown brain microglia. PLoS One (2012) 1.21
Parkinson's disease: animal models and dopaminergic cell vulnerability. Front Neuroanat (2014) 1.18
Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord (2012) 1.17
Mutant LRRK2 elicits calcium imbalance and depletion of dendritic mitochondria in neurons. Am J Pathol (2012) 1.16
Regulation of LRRK2 expression points to a functional role in human monocyte maturation. PLoS One (2011) 1.15
Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15
Gene-environment interactions: key to unraveling the mystery of Parkinson's disease. Prog Neurobiol (2011) 1.14
MicroRNA-205 regulates the expression of Parkinson's disease-related leucine-rich repeat kinase 2 protein. Hum Mol Genet (2012) 1.11
Parkinson's disease: a model dilemma. Nature (2010) 1.11
LRRK2 phosphorylates tubulin-associated tau but not the free molecule: LRRK2-mediated regulation of the tau-tubulin association and neurite outgrowth. PLoS One (2012) 1.10
Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. Hum Mol Genet (2012) 1.10
Modeling neurodegeneration in zebrafish. Curr Neurol Neurosci Rep (2011) 1.09
Animal models of Parkinson's disease: vertebrate genetics. Cold Spring Harb Perspect Med (2012) 1.08
Receptor-interacting protein (RIP) kinase family. Cell Mol Immunol (2010) 1.07
Gene-environment interactions in Parkinson's disease: the importance of animal modeling. Clin Pharmacol Ther (2010) 1.07
(G2019S) LRRK2 activates MKK4-JNK pathway and causes degeneration of SN dopaminergic neurons in a transgenic mouse model of PD. Cell Death Differ (2012) 1.07
Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays (2010) 1.06
LRRK2 and neuroinflammation: partners in crime in Parkinson's disease? J Neuroinflammation (2014) 1.05
Leucine-rich repeat kinase 2 (LRRK2) as a potential therapeutic target in Parkinson's disease. Trends Pharmacol Sci (2012) 1.04
Toxin-induced and genetic animal models of Parkinson's disease. Parkinsons Dis (2010) 1.04
Small molecule kinase inhibitors for LRRK2 and their application to Parkinson's disease models. ACS Chem Neurosci (2012) 1.04
LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. Neurobiol Dis (2010) 1.03
High LRRK2 levels fail to induce or exacerbate neuronal alpha-synucleinopathy in mouse brain. PLoS One (2012) 1.03
The role of innate and adaptive immunity in Parkinson's disease. J Parkinsons Dis (2013) 1.03
Behavioral phenotyping of mouse models of Parkinson's disease. Behav Brain Res (2010) 1.02
The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity. Cell Death Dis (2011) 0.99
Temporal expression of mutant LRRK2 in adult rats impairs dopamine reuptake. Int J Biol Sci (2011) 0.98
Progressive dopaminergic alterations and mitochondrial abnormalities in LRRK2 G2019S knock-in mice. Neurobiol Dis (2015) 0.97
α-synuclein, LRRK2 and their interplay in Parkinson's disease. Future Neurol (2012) 0.97
A direct interaction between leucine-rich repeat kinase 2 and specific β-tubulin isoforms regulates tubulin acetylation. J Biol Chem (2013) 0.97
LRRK2 pathobiology in Parkinson's disease. J Neurochem (2014) 0.97
Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain. Mol Cell Biol (2014) 0.96
Differential LRRK2 expression in the cortex, striatum, and substantia nigra in transgenic and nontransgenic rodents. J Comp Neurol (2014) 0.96
Limitations of animal models of Parkinson's disease. Parkinsons Dis (2010) 0.96
Genetic LRRK2 models of Parkinson's disease: Dissecting the pathogenic pathway and exploring clinical applications. Mov Disord (2011) 0.95
Heterogeneity of leucine-rich repeat kinase 2 mutations: genetics, mechanisms and therapeutic implications. Neurotherapeutics (2014) 0.94
LRRK2 phosphorylates novel tau epitopes and promotes tauopathy. Acta Neuropathol (2013) 0.94
Animal models of Parkinson's disease: a gateway to therapeutics? Neurotherapeutics (2014) 0.93
Axonal degeneration as a therapeutic target in the CNS. Cell Tissue Res (2012) 0.91
Dysregulated LRRK2 signaling in response to endoplasmic reticulum stress leads to dopaminergic neuron degeneration in C. elegans. PLoS One (2011) 0.91
Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse. Neurosci Lett (2013) 0.90
Evaluation of Models of Parkinson's Disease. Front Neurosci (2016) 0.90
Mitochondrial dysfunction in genetic animal models of Parkinson's disease. Antioxid Redox Signal (2011) 0.90
Surfactant secretion in LRRK2 knock-out rats: changes in lamellar body morphology and rate of exocytosis. PLoS One (2014) 0.90
WldS but not Nmnat1 protects dopaminergic neurites from MPP+ neurotoxicity. Mol Neurodegener (2012) 0.89
Assessment of sensorimotor function in mouse models of Parkinson's disease. J Vis Exp (2013) 0.89
Modeling Parkinson's disease using induced pluripotent stem cells. Curr Neurol Neurosci Rep (2012) 0.89
LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis. Exp Neurol (2014) 0.88
LRRK2: cause, risk, and mechanism. J Parkinsons Dis (2013) 0.88
Synaptic dysfunction in genetic models of Parkinson's disease: a role for autophagy? Neurobiol Dis (2010) 0.88
Contribution of GTPase activity to LRRK2-associated Parkinson disease. Small GTPases (2013) 0.87
Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi. PLoS One (2011) 0.87
Molecular insights into Parkinson's disease. F1000 Med Rep (2011) 0.87
Behavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats. Neurobiol Aging (2014) 0.87
Signal transduction protein array analysis links LRRK2 to Ste20 kinases and PKC zeta that modulate neuronal plasticity. PLoS One (2010) 0.87
Genetically engineered mouse models of Parkinson's disease. Brain Res Bull (2011) 0.86
Leucine-rich repeat kinase 2 for beginners: six key questions. Cold Spring Harb Perspect Med (2012) 0.86
Axon degeneration and PGC-1α-mediated protection in a zebrafish model of α-synuclein toxicity. Dis Model Mech (2014) 0.86
The Wld(S) mutation delays anterograde, but not retrograde, axonal degeneration of the dopaminergic nigro-striatal pathway in vivo. J Neurochem (2010) 0.85
Mitochondria: A Therapeutic Target for Parkinson's Disease? Int J Mol Sci (2015) 0.85
LRRK2 in Parkinson's disease: in vivo models and approaches for understanding pathogenic roles. FEBS J (2009) 0.85
Transgenic animal models of neurodegeneration based on human genetic studies. J Neural Transm (Vienna) (2010) 0.85
Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease? Mol Neurodegener (2011) 0.85
Parkinson's disease mouse models in translational research. Mamm Genome (2011) 0.85
Gene and MicroRNA transcriptome analysis of Parkinson's related LRRK2 mouse models. PLoS One (2014) 0.85
The role of the LRRK2 gene in Parkinsonism. Mol Neurodegener (2014) 0.85
The Parkinsonian mimetic, 6-OHDA, impairs axonal transport in dopaminergic axons. Mol Neurodegener (2014) 0.85
Rgs6 is required for adult maintenance of dopaminergic neurons in the ventral substantia nigra. PLoS Genet (2014) 0.84
LRRK2 G2019S mutation attenuates microglial motility by inhibiting focal adhesion kinase. Nat Commun (2015) 0.84
LRRK2 affects vesicle trafficking, neurotransmitter extracellular level and membrane receptor localization. PLoS One (2013) 0.84
Neurodegenerative changes initiated by presynaptic dysfunction. Transl Neurodegener (2013) 0.84
Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration. Neurobiol Dis (2014) 0.84
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron (2004) 14.35
Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron (2004) 13.99
Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci (2007) 7.96
A common LRRK2 mutation in idiopathic Parkinson's disease. Lancet (2005) 5.81
In vivo imaging of axonal degeneration and regeneration in the injured spinal cord. Nat Med (2005) 3.88
A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet (2005) 3.09
The switch of tau protein to an Alzheimer-like state includes the phosphorylation of two serine-proline motifs upstream of the microtubule binding region. EMBO J (1992) 3.04
Novel antibodies to synuclein show abundant striatal pathology in Lewy body diseases. Ann Neurol (2002) 2.70
Haplotypes and gene expression implicate the MAPT region for Parkinson disease: the GenePD Study. Neurology (2008) 2.16
A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience (2007) 1.86
Cytochrome c release and caspase activation in traumatic axonal injury. J Neurosci (2000) 1.53
Medial forebrain bundle axotomy during development induces apoptosis in dopamine neurons of the substantia nigra and activation of caspases in their degenerating axons. J Comp Neurol (2002) 1.23
Increased frequency of the LRRK2 G2019S mutation in an elderly Ashkenazi Jewish population is not associated with dementia. Neurosci Lett (2006) 1.02
Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med (2011) 69.36
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature (2006) 15.69
Parkinson's disease: mechanisms and models. Neuron (2003) 14.84
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med (2002) 9.70
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A (2009) 8.25
Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature (2011) 7.90
Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic to motor neurons. Nat Neurosci (2007) 7.77
Functional engraftment of human ES cell-derived dopaminergic neurons enriched by coculture with telomerase-immortalized midbrain astrocytes. Nat Med (2006) 7.21
Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis (2009) 6.96
Reduced-median-network analysis of complete mitochondrial DNA coding-region sequences for the major African, Asian, and European haplogroups. Am J Hum Genet (2002) 6.02
Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A (2006) 5.78
Natural variation in Ghd7 is an important regulator of heading date and yield potential in rice. Nat Genet (2008) 5.64
The draft genome of the transgenic tropical fruit tree papaya (Carica papaya Linnaeus). Nature (2008) 5.54
Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell (2002) 5.11
Pink1 regulates mitochondrial dynamics through interaction with the fission/fusion machinery. Proc Natl Acad Sci U S A (2008) 4.97
Bipolar transurethral resection of the prostate causes deeper coagulation depth and less bleeding than monopolar transurethral prostatectomy. Urology (2012) 4.61
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60
Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest (2005) 4.55
Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J Neurosci (2002) 4.38
Negative regulation of the deacetylase SIRT1 by DBC1. Nature (2008) 4.29
Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res (2003) 4.29
Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice. Nature (2002) 4.21
Parkinson's disease. Hum Mol Genet (2007) 3.84
Analysis of genetic linkage of HIV from couples enrolled in the HIV Prevention Trials Network 052 trial. J Infect Dis (2011) 3.78
Addition of a photocrosslinking amino acid to the genetic code of Escherichiacoli. Proc Natl Acad Sci U S A (2002) 3.77
RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. J Clin Oncol (2012) 3.72
The kinase domain of mitochondrial PINK1 faces the cytoplasm. Proc Natl Acad Sci U S A (2008) 3.65
Highly efficient modification of bacterial artificial chromosomes (BACs) using novel shuttle vectors containing the R6Kgamma origin of replication. Genome Res (2002) 3.61
Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol (2003) 3.54
Neural subtype specification of fertilization and nuclear transfer embryonic stem cells and application in parkinsonian mice. Nat Biotechnol (2003) 3.43
Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector. J Am Coll Cardiol (2005) 3.40
Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer. Mod Pathol (2007) 3.37
Mitochondrial biology and oxidative stress in Parkinson disease pathogenesis. Nat Clin Pract Neurol (2008) 3.35
Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med (2009) 3.32
Up-regulation of TWIST in prostate cancer and its implication as a therapeutic target. Cancer Res (2005) 3.32
Complete loss of ischaemic preconditioning-induced cardioprotection in mice with partial deficiency of HIF-1 alpha. Cardiovasc Res (2007) 3.31
Intraneuronal Alzheimer abeta42 accumulates in multivesicular bodies and is associated with synaptic pathology. Am J Pathol (2002) 3.23
Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy. J Clin Invest (2008) 3.23
Urbanisation and health in China. Lancet (2012) 3.21
A recalibrated molecular clock and independent origins for the cholera pandemic clones. PLoS One (2008) 3.16
Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-γ and TNF-α. Nat Med (2011) 3.11
Regulation of hepcidin transcription by interleukin-1 and interleukin-6. Proc Natl Acad Sci U S A (2005) 3.11
Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med (2013) 3.10
Lysine propionylation and butyrylation are novel post-translational modifications in histones. Mol Cell Proteomics (2007) 3.09
Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc Natl Acad Sci U S A (2004) 3.06
Mitochondria: the next (neurode)generation. Neuron (2011) 3.06
Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. Cancer Res (2008) 3.02
Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc (2007) 3.00
NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc Natl Acad Sci U S A (2003) 2.91
A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis (2006) 2.88
Addition of p-azido-L-phenylalanine to the genetic code of Escherichia coli. J Am Chem Soc (2002) 2.88
DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A (2007) 2.87
A fluorescence in situ hybridization screen for E26 transformation-specific aberrations: identification of DDX5-ETV4 fusion protein in prostate cancer. Cancer Res (2008) 2.87
Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron (2003) 2.80
Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci U S A (2004) 2.77
Cyclooxygenase-2 is instrumental in Parkinson's disease neurodegeneration. Proc Natl Acad Sci U S A (2003) 2.74
Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends Mol Med (2008) 2.74
Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression. Mod Pathol (2009) 2.69
Mutated human SOD1 causes dysfunction of oxidative phosphorylation in mitochondria of transgenic mice. J Biol Chem (2002) 2.68
Complete reconstitution of a highly reducing iterative polyketide synthase. Science (2009) 2.68
Gliosis and brain remodeling after treatment of stroke in rats with marrow stromal cells. Glia (2005) 2.68
Toxin-induced models of Parkinson's disease. NeuroRx (2005) 2.67
Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol (2010) 2.67
Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A (2002) 2.64
Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med (2011) 2.62
Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res (2003) 2.61
Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res (2007) 2.60
Image-based genome-wide siRNA screen identifies selective autophagy factors. Nature (2011) 2.58
Inactivation of Drosophila DJ-1 leads to impairments of oxidative stress response and phosphatidylinositol 3-kinase/Akt signaling. Proc Natl Acad Sci U S A (2005) 2.58
Not so crystal clear: the structure of the human telomere G-quadruplex in solution differs from that present in a crystal. Nucleic Acids Res (2005) 2.57
Mitochondrial alpha-ketoglutarate dehydrogenase complex generates reactive oxygen species. J Neurosci (2004) 2.57
Genomic sequencing reveals regulatory mutations and recombinational events in the widely used MC4100 lineage of Escherichia coli K-12. J Bacteriol (2009) 2.51
Clinical, experimental, and genomic differences between intermediately pathogenic, highly pathogenic, and epidemic Streptococcus suis. J Infect Dis (2009) 2.49
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem (2011) 2.46
Near-infrared fluorescent nanoparticles as combined MR/optical imaging probes. Bioconjug Chem (2002) 2.45
CXCR4 regulates interneuron migration in the developing neocortex. J Neurosci (2003) 2.44
Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem (2004) 2.43
Activated neural stem cells contribute to stroke-induced neurogenesis and neuroblast migration toward the infarct boundary in adult rats. J Cereb Blood Flow Metab (2004) 2.41
Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. Neoplasia (2006) 2.39
Ischemic rat brain extracts induce human marrow stromal cell growth factor production. Neuropathology (2002) 2.38
Correlates of HIV acquisition in a cohort of Black men who have sex with men in the United States: HIV prevention trials network (HPTN) 061. PLoS One (2013) 2.32
Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci (2003) 2.31
Tembusu virus in ducks, china. Emerg Infect Dis (2011) 2.30
Pitx3 is required for development of substantia nigra dopaminergic neurons. Proc Natl Acad Sci U S A (2003) 2.27
D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. J Clin Invest (2003) 2.25
Thermal diode: rectification of heat flux. Phys Rev Lett (2004) 2.24
Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A (2009) 2.23
Rapamycin protects against neuron death in in vitro and in vivo models of Parkinson's disease. J Neurosci (2010) 2.15